Morgan Stanley analyst Matthew Harrison has maintained an Equal-Weight rating on Biogen (NASDAQ: BIIB) and raised the price target to $224 from $206. The revised target indicates an updated valuation perspective on the stock while retaining a neutral stance on its performance potential.

Rating and Price Action

The research note confirms the Equal-Weight designation, suggesting the stock is expected to perform in line with the broader market. The increase in the price target to $224 signals a more optimistic view on the stock's upside compared to the previous $206 level.

Key Details

The adjustment comes as analysts reassess Biogen's position within the biotechnology sector.

Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. regarding potential violations of federal securities laws. The investigation focuses on whether Biogen and certain of its officers and/or directors engaged in securities fraud or other unlawful business practices. This scrutiny follows the company's announcement regarding the Phase 2 CELIA study evaluating diranersen (BIIB080), an investigational antisense oligonucleotide therapy targeting tau in individuals with early Alzheimer's disease.

On May 14, 2026, Biogen issued a press release announcing topline results from the study. Although the company described the results as "compelling," the study missed its primary dose-response endpoint. Following this news, Biogen's stock price fell $13.16 per share, or 6.43%, to close at $191.37 per share on the same day.

The legal review aims to determine if investors suffered losses due to potential securities law violations related to these disclosures. Pomerantz LLP, acknowledged as a premier firm in corporate, securities, and antitrust class litigation, is conducting the investigation. The firm has offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv.

Investors who incurred losses are encouraged to participate. Danielle Peyton at Pomerantz LLP is available to discuss investor rights. Shareholders can contact the firm at newaction@pomlaw.com or by phone at 646-581-9980, ext. 7980.

Pomerantz LLP was founded by the late Abraham L. Pomerantz, known as the dean of the class action bar. The firm has recovered numerous multimillion-dollar damages awards on behalf of class members. Additional information is available at www.pomlaw.com .